Your Catalyst to a Lucrative Business
This trend is expected to continue over the next few years. Rising geriatric population is also anticipated to
contribute toward the market expansion in the years to come. The main challenge this indust ry is facing is
emergence of drug resistant strains. As in the category of drugs, antibacterial drugs have various unique
characteristics, which make them little less profitable and therefore less attractive investments. These drugs
are prescribed for short course of time, anywhere from 4 days to 2 weeks as compared to the medications for
cholesterol and anti-hypertensive patients, which last for several years or decades. Innovation in technical
development is the key opportunity for the market. Numerous companies in this field are continually
investing to develop new, advanced products in order to increase their product portfolio.
Major attention is focused on research and development of vital but less profitable antibacterial drug for the
companies to sell at a premium price. The demand for antibiotics is rising particularly to treat children with
pneumonia and sepsis. In most countries, 20% of the product is used by healthcare facilities and hospitals
while 80% is used by the community. These are either purchased directly by the consumers or are presc ribed
by the healthcare providers.
Browse Details of Report @ https://www.hexaresearch.com/research-report/antibiotics-market
Antibiotics can be classified into seven major classes namely phenicols, quinolones, macrolides,
sulfonamides, aminoglycosides, tetracyclines, and beta lactams. Around half of the market share was claimed
by beta lactams class in the past. The second largest class was quinolones. However, the market will
experience a decline as a result of the adverse effects on sales due to patent expiries. However,
fluoroquinolones/quinolones is expected to foresee a significant demand in the market over the forecast
period as they are used in treating a large number of infections.
Some of the key companies operating in the global market are Pfizer, Inc.; Abbott Laboratories;
GlaxoSmithKline PLC; Daiichii Sankyo Company Limited; Bayer HealthCare Pharmaceuticals LLC; Astellas
Pharma, Inc.; Merck & Company, Inc.; Roche Holding AG; Bristol-Myers Squibb Co., Cubist Pharmaceuticals,
Inc.; GlaxoSmithKline Plc; Pliva d.dd; Toyama Chemica Co. Ltd.; Takeda Pharmaceutical Company. Ltd.;
Johnson & Johnson; LG Life Sciences Limited; and Eli Lilly and Co. Pfizer Inc. contributed to the largest share
in the past, followed by GlaxoSmithKline PLC and Merck & Company, Inc. With very few patented products
available at present, generic manufacturers are leading the global market for antibiotics.
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-
industry
Follow Us: